



22 May 2014
EMA/124022/2014, rev.1
Press Office

Guidelines and concept papers

Adopted during the CHMP meeting 19-22 May 2014

The guidelines and concept papers which have been adopted during this meeting of the Committee for Medicinal Products for Human Use (CHMP) will be published shortly on the European Medicines Agency's website under [Regulatory/Human/Scientific guidelines](#). Documents for public consultation will also be available under [Document search/Public consultations](#).

Biologics Working Party

Reference number	Document	Status
EMA/CHMP/BWP/799297/2013	Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)	Adopted

Blood Products Working Party

Reference number	Document	Status
EMA/CHMP/BPWP/572810/2013	Concept paper on the need for revision of the Guideline on the clinical investigation of plasma derived fibrin sealant/haemostatic products	Adopted for 3-months public consultation

Safety Working Party

Reference number	Document	Status
EMA/CHMP/495737/2013	Q&A on Benzalkonium chloride	Adopted for 3-month public consultation



Oncology Working Party

Reference number	Document	Status
EMA/CHMP/292465/2013	Reflection Paper on the use of Patient Reported Outcome (PRO) measures in oncology studies"	Adopted for 6-months public consultation

Name Review Group

Reference number	Document	Status
EMA/CHMP/287710/2014 – Rev. 6	Guideline on the acceptability of names for human medicinal products processed through the centralised procedure	Adopted